The treatment options available in cases of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are very limited. In a recent issue of Leukemia, Taksin et al.
1 described the high efficacy and safety of fractionated doses of gemtuzumab ozogamicin (GO) as induction therapy in patients with relapsed AML; fractionated doses of GO (3 mg m À2 ) were used on days 1, 4 and 7 for one course of therapy, with 26% of patients achieving complete remission (CR) and 7% achieving CR with incomplete platelet recovery (CRp) with low toxicity.
Here, we report an adult patient with AML who relapsed after allo-HSCT. This female patient had the translocation t(6;11) with transcription of MLL/AF6 fusion mRNA in her leukemic cells.
In contrast to Taksin et al., 1 who suggested fractionated doses of GO as reinduction therapy, we applied a strategy involving a normal dose of GO (9 mg m À2 ) with a long interval between the courses of administration (days 1 and 21) followed by donor lymphocyte infusion (DLI).
The patient, a 38-year-old woman, presented with AML, French-American-British (FAB) classification M1, with translocation t(6;11) and MLL/AF6 rearrangement. Her leukemic cells were positive for CD33 antigen. First hematological CR was achieved on day 27 after administration of one course of highdose cytarabine (Ara-C), and fluorescence in situ hybridization (FISH) analysis showed no mixed lineage leukemia (MLL) splitting. However, minimal residual disease (MRD) was detected by polymerase chain reaction (PCR) analyses. She underwent bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-identical sibling after conditioning with total-body irradiation (TBI) at a dose of 12 Gy and 60 mg kg À1 cyclophosphamide (CY). No graft-versus-host disease (GVHD) occurred with cyclosporine (CyA) and short-term methotrexate (MTX) as prophylaxis. The patient achieved molecular CR on day 90.
On day 260, molecular relapse was noted although the patient was still in hematological CR.
The first hematological relapse was diagnosed at 11 months after BMT, at which time we applied aggressive reinduction chemotherapy (idarubicin þ Ara-C þ etoposide). However, the chemotherapy did not have a sufficient effect. The patient developed severe oral mucositis and sepsis as a result of the chemotherapy. We selected a strategy involving administration of normal doses of GO (9 mg m À2 ) with a long interval between the courses of treatment (days 1 and 21) followed by DLI (day 60) because additional aggressive reinduction chemotherapy was not feasible in this case.
The patient achieved molecular CR by GO on day 45 and subsequent DLI was performed on day 60. No grade 3 or 4 liver toxicity or veno-occlusive disease occurred after GO. No signs of GVHD were observed. Molecular relapse was again noted on day 182 (1500 copies per mg RNA of MLL/AF6), but the MRD decreased subsequently with no additional therapy.
The MRD level was 260 copies per mg RNA of MLL/AF6 on day 200, and the patient retained hematological CR on day 240.
Adult AML with MLL/AF6 is the most unfavorable risk group in AML with 11q23/MLL abnormalities.
2 Even allogeneic stem cell transplantation is of limited benefit in AML patients with MLL beyond the first CR or with the primary refractory disease.
3
GO is one of the forms of therapy that can be used in cases of relapsed AML. A pivotal phase II study in AML in the first relapse used GO at a dose of 9 mg m À2 on days 1 and 14. 4 This study showed a 26% response (13% CR and 13% CRp) but with high degrees of hematological and liver toxicity. Taksin et al. reported the high efficacy and good safety profile of fractionated doses of GO as induction therapy in patients with relapsed AML. This protocol of GO is very useful in limited strategies in relapsed AML. We attempted to reduce the toxicity of GO not by fractionation but by having a longer interval between the courses of treatment. However, further studies in large number of cases are required to adequately assess the safety of this approach.
This case was unusual in that molecular relapse after GO and DLI decreased with no additional therapy, which seemed to be due to a graft-versus-leukemia (GVL) effect. These results are very encouraging and suggest that GO with a long interval followed by DLI can result in at least 8 months of hematological CR in limited strategies in relapsed AML with MLL/AF6 after allo-HSCT (Figure 1) .
Moreover, Muñ oz et al. 5 reported clinical features of adult acute leukemia with 11q23 abnormalities. In this previous study, 12 of 13 (92.3%) cases of AML with MLL expressed CD33 antigen. These results also support the usefulness of GO in AML with MLL.
Further studies are required to determine the effects of GO followed by DLI or this combination followed by a second round of allo-HSCT on the prognosis of relapsed AML with MLL/AF6 after allo-HSCT in large number of cases.
Figure 1
Clinical course of the patient: hematological relapse ; high-dose Ara-C ' ; allo-HSCT }; idarubicin þ Ara-C þ etoposide &; GO.; DLI~. MicroRNAs (miRNAs) are small noncoding RNAs of 20-24 nucleotides (nt) that negatively regulate the translation of target mRNAs through incomplete base-pairing with their 3 0 -untranslated regions.
1 Evidence indicates that miRNAs play an important role in the development of human cancers including leukemias, with one of the most well-characterized examples being association of miR-15a and miR-16a with chronic lymphocytic leukemia. Almost half of chronic lymphocytic leukemia patients harbor a chromosome deletion that encompasses 13q14, a region that includes the genes for miR-15a and miR-16a, and the abundance of these miRNAs is reduced in chronic lymphocytic leukemia cells with the chromosome deletion.
2 Several other miRNAs, such as miR-155 and miR-17-92, have also been implicated in the pathogenesis of lymphoma.
3 It is therefore important that the entire miRNA repertoire of clinical specimens be characterized and compared among various hematologic malignancies.
Reliable assessment of the global expression profiles of miRNAs, especially for the small amounts of clinical specimens available, is not straightforward, however. Microarray-based detection of miRNAs is prone to the generation of false-positive data that may result from mishybridization of probes, although improvements have recently been developed for this technology.
4 A large-scale cloning strategy would be an ideal approach to reliable estimation of the expression level of miRNAs, provided that a sufficient number of clones were to be analyzed. However, conventional methods for isolation of miRNAs require 410 mg of total RNA, which is not always obtainable from clinical specimens.
We recently developed a sensitive method, mRAP (micro RNA amplification profiling) 5 that readily allows the isolation of miRNA clones from p1 Â 10 4 cells. To examine the miRNA expression profiles for leukemias with mRAP, we first purified CD34 þ cells from individuals (n ¼ 12) with de novo acute myeloid leukemia, acute myeloid leukemia secondary to myelodysplastic syndrome, acute lymphoid leukemia or biphenotypic acute leukemia (Table 1) . Column affinity-chromatography to isolate CD34 þ cells yielded 10-50% of the input cells with a purity of X90% as judged by flow cytometry (data not shown). As a normal control, we also purified a CD34 þ cell fraction from bone marrow mononuclear cells of a healthy volunteer. Then mRAP procedure was applied to 1.1 Â 10 6 -1.0 Â 10 8 of the purified CD34 þ cells from each individual in order to obtain short RNA clones.
Sequencing and computer filtering 5 of the mRAP amplicons identified a total of 38 858 qualified reads for the 13 study subjects. BLAST analysis then isolated 32 867 reads that match the human genome sequence (ncbi 36 assembly), among which 2054 reads were mapped to transfer RNA genes, 2720 to ribosomal RNA genes and 9474 to repetitive sequences. From the remaining sequences, we identified 7191 reads corresponding to 143 independent known miRNAs (Supplementary Table 1 ). We further searched for candidate sequences corresponding to novel miRNAs whose surrounding genome sequences (of B100 nt) potentially fold into a hairpin structure with a single notch. In this analysis, we did not exclude miRNA candidates that were not detected in the genomes of other Table 1 Clinical characteristics of the study subjects
